Eli Lilly & Company

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises

The Dutch buildout underscores a bet on scalable oral GLP-1 supply ahead of an orforglipron obesity filing targeted for late 2025.